Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ALUR NASDAQ:NVNO NASDAQ:STSS NASDAQ:XAGE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALURAllurion Technologies$2.13+0.5%$2.61$1.98▼$22.25$16.46M-0.4663,311 shs40,029 shsNVNOenVVeno Medical$0.79+1.1%$3.68$0.76▼$5.70$15.02M0.872.08 million shs602,539 shsSTSSSharps Technology$10.45-12.3%$6.84$3.36▼$2,145.00$12.19M2.313.09 million shs748,492 shsXAGELongevity Health$2.55+8.1%$2.96$2.15▼$38.10$4.20M0.5124,485 shs55,581 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALURAllurion Technologies+0.96%-4.75%-26.14%-22.75%-87.54%NVNOenVVeno Medical-3.79%-13.70%-83.88%-77.58%-85.28%STSSSharps Technology+1.62%-19.74%+158.35%+105.70%+1,190,999,900.00%XAGELongevity Health-8.53%-13.55%-16.90%+235,999,900.00%+235,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALURAllurion Technologies$2.13+0.5%$2.61$1.98▼$22.25$16.46M-0.4663,311 shs40,029 shsNVNOenVVeno Medical$0.79+1.1%$3.68$0.76▼$5.70$15.02M0.872.08 million shs602,539 shsSTSSSharps Technology$10.45-12.3%$6.84$3.36▼$2,145.00$12.19M2.313.09 million shs748,492 shsXAGELongevity Health$2.55+8.1%$2.96$2.15▼$38.10$4.20M0.5124,485 shs55,581 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALURAllurion Technologies+0.96%-4.75%-26.14%-22.75%-87.54%NVNOenVVeno Medical-3.79%-13.70%-83.88%-77.58%-85.28%STSSSharps Technology+1.62%-19.74%+158.35%+105.70%+1,190,999,900.00%XAGELongevity Health-8.53%-13.55%-16.90%+235,999,900.00%+235,999,900.00%Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALURAllurion Technologies$32.11M0.51N/AN/A($30.08) per share-0.07NVNOenVVeno MedicalN/AN/AN/AN/A$2.40 per shareN/ASTSSSharps TechnologyN/AN/AN/AN/A$110.01 per shareN/AXAGELongevity Health$50K90.78N/AN/A($6.77) per share-0.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALURAllurion Technologies-$7.20M-$12.53N/AN/AN/A-158.30%N/A-59.91%11/12/2025 (Estimated)NVNOenVVeno Medical-$21.82M-$1.20N/AN/AN/AN/A-57.35%-53.49%10/29/2025 (Estimated)STSSSharps Technology-$9.30M-$1,212.34N/A∞N/AN/A-8.72%-5.30%N/AXAGELongevity Health-$10.37MN/A0.00∞N/A-682.67%N/A-261.90%N/ALatest XAGE, ALUR, NVNO, and STSS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/19/2025Q2 2025ALURAllurion Technologies-$0.65-$0.57+$0.08-$1.28$6.20 million$3.38 million8/14/2025Q2 2025XAGELongevity HealthN/A-$1.56N/A-$1.56N/A$0.50 million8/13/2025Q2 2025STSSSharps Technology-$0.94$3.58+$4.52$3.58$0.25 million$0.22 million7/31/2025Q2 2025NVNOenVVeno Medical-$0.28-$0.33-$0.05-$0.33N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALURAllurion TechnologiesN/AN/AN/AN/AN/ANVNOenVVeno MedicalN/AN/AN/AN/AN/ASTSSSharps TechnologyN/AN/AN/AN/AN/AXAGELongevity HealthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALURAllurion TechnologiesN/A2.021.70NVNOenVVeno MedicalN/A11.8111.81STSSSharps TechnologyN/A4.353.67XAGELongevity HealthN/A0.470.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALURAllurion Technologies21.39%NVNOenVVeno Medical34.71%STSSSharps Technology17.17%XAGELongevity Health24.22%Insider OwnershipCompanyInsider OwnershipALURAllurion Technologies22.40%NVNOenVVeno Medical16.00%STSSSharps Technology0.15%XAGELongevity Health29.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALURAllurion Technologies5017.76 million6.02 millionOptionableNVNOenVVeno Medical3019.25 million16.17 millionOptionableSTSSSharps Technology31.02 million1.02 millionNot OptionableXAGELongevity Health141.78 million1.27 millionN/AXAGE, ALUR, NVNO, and STSS HeadlinesRecent News About These CompaniesWhy Longevity Health Stock Is Skyrocketing TodayJuly 15, 2025 | benzinga.comWhy Longevity Health Stock Is Skyrocketing TodayJuly 15, 2025 | benzinga.comWhy did XAGE Stock Surge in Today’s Premarket Trading?July 15, 2025 | tokenist.comTLongevity Health Holdings, Inc.: Longevity Health Holdings Announces Merger with THPlasma and Termination of 20/20 BioLabs TransactionJuly 15, 2025 | finanznachrichten.deLongevity Health Holdings to Merge With True HealthJuly 15, 2025 | marketwatch.comLongevity Health stock soars after merger with THPlasma in all-stock dealJuly 15, 2025 | investing.comLongevity Health Holdings Announces Merger with THPlasma and Termination of 20/20 BioLabs TransactionJuly 14, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXAGE, ALUR, NVNO, and STSS Company DescriptionsAllurion Technologies NYSE:ALUR$2.13 +0.01 (+0.47%) Closing price 03:59 PM EasternExtended Trading$2.12 0.00 (-0.23%) As of 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.enVVeno Medical NASDAQ:NVNO$0.79 +0.01 (+1.12%) Closing price 04:00 PM EasternExtended Trading$0.78 -0.01 (-1.64%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial. Sharps Technology NASDAQ:STSS$10.45 -1.46 (-12.26%) Closing price 04:00 PM EasternExtended Trading$10.26 -0.19 (-1.87%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sharps Technology, Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. Sharps Technology, Inc. was incorporated in 2017 and is based in Melville, New York.Longevity Health NASDAQ:XAGE$2.55 +0.19 (+8.05%) As of 04:00 PM EasternCarmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Insider Selling: Risk Signal or Normal Activity? Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Affirm Crushes Earnings Expectations, Turns Bears into Believers Gold’s Explosive Rally: GDX ETF May Be the Fast Track to Profits Dollar Tree Plunges Into Buy-Zone: A Robust Rebound Is Expected Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
